(April 20, 2016, 12:17 PM EDT) -- MARSHALL, Texas — Efforts by Mylan Pharmaceuticals Inc. and Mylan Inc. (Mylan, collectively) to dismiss patent infringement allegations stemming from generic Restasis were unsuccessful April 19, when Circuit Judge William C. Bryson of the Federal Circuit U.S. Court of Appeals ruled that the case may proceed (Allergan Inc. v. Mylan Pharmaceuticals Inc., et al., No. 15-1455, E.D. Texas; 2016 U.S. Dist. LEXIS 51851)....